Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B
- 30 January 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 68 (2) , 397-400
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis BHepatology, 2017
- Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE studyJournal of Hepatology, 2017
- Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg‐negative chronic hepatitis BHepatology, 2017
- Hepatitis B cure: From discovery to regulatory approvalHepatology, 2017
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 updateHepatology International, 2015
- AASLD guidelines for treatment of chronic hepatitis BHepatology, 2015
- Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With AdefovirGastroenterology, 2012